With its Bexxar tositumomab under review at the FDA, Coulter Pharmaceutical Inc. hopes to create a pipeline by competing against numerous other companies to in-license drug candidates. To make itself a more attractive partner in the therapeutic antibody arena, CLTR last week obtained access to a technology that the company said will provide it with a stable, high-level expression system for recombinant antibodies while simultaneously providing faster recombinant protein production for research.

CLTR (South San Francisco, Calif.) and Cobra Therapeutics Ltd. (Keele, U.K.), a subsidiary